Stockscreener 앱 받기
1.44
9.43%
-0.15
시간 외 거래:
1.43
-0.01
-0.69%
전일 마감가:
$1.59
열려 있는:
$1.54
하루 거래량:
137.71K
Relative Volume:
0.05
시가총액:
$52.35M
수익:
-
순이익/손실:
$-87.23M
주가수익비율:
-0.4848
EPS:
-2.97
순현금흐름:
$-82.77M
1주 성능:
-10.00%
1개월 성능:
+31.51%
6개월 성능:
-78.95%
1년 성능:
-89.86%
1일 변동 폭
$1.43
$1.59
1주일 범위
$1.40
$1.64
52주 변동 폭
$0.8801
$19.30
Pepgen Inc Stock (PEPG) Company Profile
명칭
Pepgen Inc
전화
703-456-8000
주소
1 MARINA PARK DRIVE, SUITE 900, BOSTON
PEPG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.44 | 52.35M | 0 | -87.23M | -82.77M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-07-31 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-21 | 개시 | H.C. Wainwright | Buy |
Pepgen Inc 주식(PEPG)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
PepGen Inc. CEO Makes Bold Stock Purchase! - TipRanks
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
PepGen Inc.’s CEO Makes Bold Stock Purchase! - TipRanks
PepGen president and CEO McArthur buys shares worth $47,724 By Investing.com - Investing.com Canada
PepGen president and CEO McArthur buys shares worth $47,724 - Investing.com
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Canada
PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa
PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
PepGen Announces Appointment of Two New Directors to its Board - BioSpace
PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz
PepGen Inc. Expands Board with New Appointments - TipRanks
PepGen names two new directors to board - TipRanks
PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia
PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph
PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire
PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks
What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register
PepGen pauses Phase II DMD trial to review safety data - Clinical Trials Arena
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com
Boston biotech's stock drops after Duchenne trial pause - The Business Journals
PepGen to pause CONNECT2-EDO51 study - TipRanks
PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView
PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com
PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView
PepGen to Participate in Upcoming Investor Conferences - Business Wire
Pepgen Inc (PEPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):